Octreotide Acetate Injection: Indications, Pharmacology, Warnings, and Precautions

Overview:

Octreotide acetate injection is a conventional and age-old therapeutic choice for tackling acromegaly, a peculiar medical state instigated by overstated growth hormone secretions. In 1988, the United States Food and Drug Administration licensed octreotide acetate for acromegaly. Since then, Octreotide acetate has been employed in different formulations, including long-acting Octide and slow-release Octide formulations. Apart from acromegaly, Octreotide acetate injections are also instituted for certain tumors.

Drug Group:

Somatostatin analog is the drug group that accommodates Octreotide acetate injection. As the name suggests, the somatostatin analogs mimic and take over the role of somatostatins, an intrinsic hormone that modulates and mutes the release of growth hormone.

Available Doses and Dosage Forms:

1. Dosage Form: Octreotide acetate injection solution.

2. Available Doses:

• 50 micrograms per milliliter.

• 100 micrograms per milliliter.

• 500 micrograms per milliliter.

For Patients:

What Is Acromegaly?

A derangement in growth hormone secretion invokes Acromegaly. Growth hormones are imperative for the body’s physical growth and development, and the pituitary gland is the key manufacturer of growth hormones. Acromegaly is a medical state inflicted by overstated growth hormone liberation from the pituitary gland in an adult individual who has already attained the intended growth.

Overstated discharge of growth hormone in an adult individual blows up and expands certain bones and cartilage, prompting an enlarged jaw, hands, feet, fingers, and toes and a prominent forehead. Acromegaly could be brought out by tumorous growth in the pituitary gland (pituitary adenoma). The condition advances at a slower pace, gradually inflicting manifestations like joint pain, headache, excess sweating, deepening voice, visual disturbances, wrist pain, and snoring. If the growth hormone excess is encountered before puberty, then it would bring forth another medical condition called gigantism, instigating overstated lengthening of the bones, prompting an unexplainable hike in one’s height. The impact or aftermath of acromegaly could be mitigated by muting the expression of excess growth hormones. Somatostatin analogs are the most commonly chosen therapeutics for acromegaly patients.

How Does Octreotide Acetate Injection Work?

Octreotide acetate injection, a somatostatin analog, simulates the functions of somatostatin, which suppresses and holds back the growth hormone. As acromegaly is brought out by overstated growth hormone release, Octreotide acetate injections gear down the progression of acromegaly by palliating the growth hormone release. Once the growth hormone release is mitigated, the insulin-like growth factor level also scales down, increasing and intensifying the inhibition of aberrant growth. This is how octreotide acetate injection works to mitigate the effects of acromegaly.

What Is the Dose of Octreotide Acetate Injection?

1. Initial Dosage:

• Dose: 50 micrograms (mcg) of Octreotide Acetate injection.

• Dosing Frequency: Thrice daily.

• Duration: First 14 days.

2. Maintenance Dosage:

• Dose: 100 to 500 micrograms.

• Dosing Frequency: Thrice daily.

How Effective Is Octreotide Acetate Injection?

Octreotide acetate injection’s effectivity attributes in tackling acromegaly are well explored through clinical studies. It could appreciably downturn the growth hormone release, and thus, the gravity for abnormal and exaggerated growth can be halted and stamped out. 60 to 70 percent of acromegaly cases addressed with Octreotide acetate injections expressed palliation in the exaggerated growth hormone release, and most patients attained normalcy in the growth hormone proportions.

What Are the Things to Inform the Doctor Before Taking the Drug?

Here are certain things that one should inform the doctors before Octreotide acetate injection therapy:

• Any allergic encounter with Octreotide Acetate.

• Allergy to any of the elements in Octreotide acetate injection.

• Concurrent medicinal therapies and past medications, particularly those that have been used in the recent past.

• Herbal products and dietary supplements that the person uses.

• Health information about the person encompasses medical conditions or ailments (elevated blood sugar, kidney disease, or liver disease).

• Pregnancy and breastfeeding status.

How Is Octreotide Acetate Injection Administered?

Octreotide acetate injections must be delivered into the vein (intravenous injections) or underneath the skin (subcutaneous injection). A long-acting formulation of Octreotide acetate is instituted for delivery into muscles (intramuscular injection). As it is long-acting, the dosing frequency is once every four weeks, while immediate-release injection formulations must be delivered two to three times a day.

The Octreotide Acetate injection formulation must be diluted with the required quantity of diluent, which will be quoted on the medicine’s label. The medicine’s manufacturing company gives the dilution and other instructions and may express slight variances with the company. Before delivering the Octreotide acetate injection, ascertain that the solution is homogeneous with no undesirable color variations or particulate matter.

What Are the Side Effects of Octreotide Acetate Injection?

Some of the side effects that Octreotide acetate injection could bring out include:

• Constipation.

• Diarrhea.

• Stomach pain.

• Nosebleed.

• Foul-smelling stool.

• Joint pain.

• Soreness at the injection point.

• Hair loss.

• Visual disturbances.

• Tiredness.

• Dizziness.

• Yellow skin.

• Deranged heartbeat.

• Facial puffiness.

• Throat tightness.

• Breathing issues.

• Heavy menstrual bleeding.

• Dry skin.

• Skin rashes.

• Itchy skin.

• Brittle and weak hair and nails.

• Cold sensitivity.

Dietary Considerations:

Octreotide acetate injection therapy does not mandate dietary modification. However, if the doctor recommends any such considerations, they should be followed.

Missed Dose:

• For Immediate Release Octreotide Acetate Injection: The missed dose of Octreotide Acetate injection can be disregarded and skipped if the subsequent dose is close by.

• For Long-Acting Octreotide Acetate Injection: Get medical advice on how to proceed with the dosing in instances of an overlooked long-acting Octreotide dose.

Overdose:

Delivering Octreotide acetate subcutaneously in doses that outrun the desired level could bring out overdosing issues. If octreotide acetate overdosing is suspected, reach out for medical help or the poison control helpline so that immediate medical assistance can be sought.

Storage:

• Storage Temperature: Two to eight degrees Celsius (36 to 46 degrees Fahrenheit).

• Storage Condition: Refrigeration.

• Shelf Life Under Room Temperature: 14 days.

For Doctors:

Indications:

• Acromegaly (when surgical and other non-surgical interventions are unproductive).

• Metastatic carcinoid tumors.

• Vasoactive intestinal peptide tumors (VIPomas).

Dose:

1. For Acromegaly:

Fifty micrograms of Octreotide acetate are instituted as the initial dosing regimen at a daily dosing frequency of three via the subcutaneous route. The growth hormone proportions ought to be weighed up periodically and tracked. Accordingly, a necessary upregulation in Octreotide acetate dosing could be employed in the maintenance dose to modulate the growth hormone proportions within the healthy range. Maintenance doses range from 100 to 500 micrograms, instituted at a daily frequency of three. The scope for adverse outcomes is heightened when the Octreotide dose exceeds 300 micrograms per day.

2. For Carcinoid Tumors:

For the first 14 days, 100 to 500 micrograms of Octreotide acetate per day could be advocated in divided doses via subcutaneous route. The recommended maintenance dose is approximately 450 micrograms per day.

3. For Vasoactive Intestinal Peptide Tumors:

Subcutaneous delivery of 200 to 30 micrograms of Octreotide acetate is advocated as the daily dose for vasoactive intestinal peptide tumors. The daily dose needs to be divided into smaller doses.

Dosing Considerations:

Octreotide acetate injection therapy needs to be paused for four weeks every year. This withdrawal for four weeks every year is advocated for those who are exposed to irradiation.

What Are the Pharmacological Aspects of Octreotide Acetate Injection?

1. Mechanism of Action: Being a somatostatin analog, Octreotide acetate simulates somatostatin’s role. Somatostatins are the intrinsic agents that downturn growth hormone liberation. However, the inhibitory attributes of Octreotide acetate against growth hormone excel and outdo those of somatostatin, and therefore, Octreotide’s potency is also much appreciated in downscaling the manifestations. In addition to palliation in growth hormone liberation, Octreotide could also bring out other effects like:

• Downturns luteinizing hormone secretion.

• Depletes splanchnic blood flow.

• It suppresses gastrin, secretin, and motilin.

• Compromised response to GnRH (gonadotropin-releasing hormone).

2. Pharmacodynamics:

Both growth hormone and insulin-like growth factor -1 (IGF-1) proportions attain normalcy with Octreotide acetate injection therapy. Apart from Octreotide acetate’s prime action on growth hormone release, there are other pharmacodynamic attributes that it could bring out in the body. Gall bladder contractility significantly declines even with a single Octreotide Acetate injection dose. In addition, bile secretion is compromised by octreotide acetate injection. The thyroid-stimulating hormone also palliates with Octreotide injection.

3. Pharmacokinetics:

Subcutaneous delivery of Octreotide acetate ascertains swift and prompt absorption and uptake from the injected point. Peak concentration is expressed 0.4 hours after the subcutaneous introduction of Octreotide acetate. 5.2 nanograms per milliliter is estimated as the peak concentration attained after introducing a 100 microgram Octreotide Acetate injection dose. Octreotide acetate disseminates and distributes into the circulation by attaching to lipoproteins and plasma proteins. 1.7 to 1.9 is the estimated half-life of the Octreotide Acetate injection formulation. Octreotide acetate metabolizes and breaks down through hydrolysis and oxidation, which occur in the liver. However, around 35 percent of the injected dose is eliminated in raw form, unchanged. The urinary route is the key elimination pathway for Octreotide acetate.

Toxicity:

In animal studies, no mutagenic or carcinogenic attributes were underscored with Octreotide acetate injection. Carcinogenicity potency was assessed in mice at a dose that approximates eight times the human dose. However, animal studies with more than twice the human dose of Octreotide acetate revealed carcinomas and sarcomas, particularly at injection points. No instances of tumors were evidenced in humans who underwent Octreotide Acetate injection therapy for up to five years.

Delivering Octreotide acetate in a dosage exceeding the intended limit could bring forth overdosing issues.

Some of the clinical manifestations shown up with Octreotide acetate overdosing include the following:

• Hypotension.

• Arrhythmia.

• Atrioventricular block.

• Brain hypoxia.

• Hepatitis steatosis.

• Lactic acidosis.

• Pancreatitis.

• Diarrhea.

• Hepatomegaly.

• Lethargy.

• Weight loss.

Clinical Studies:

Several clinical studies have weighed the therapeutic attributes and safety concerns prompted by Octreotide acetate injection therapy in acromegaly patients. More than 60 percent of acromegaly patients who were trialed with Octreotide injections expressed a remarkable downturn in growth hormone release. The exaggerated growth hormone release that has inflicted acromegaly returned to its healthy proportion with Octreotide injection therapy in the subjects trialed with Octreotide therapy. The normalcy in growth hormone proportions also kept up in the long run with Octreotide injection therapy, which underscored the efficacy of the medicament in long-term therapies.

Contraindications of Octreotide Acetate Injection

• Octreotide acetate allergy.

• Allergic to any of the elements in Octreotide acetate injection formulation.

Warnings and Precautions:

• Deranged Cardiac Functions: Octreotide acetate injection therapy increases the threat of grave cardiac issues, including a higher degree of atrioventricular block. In addition, electrocardiogram (ECG) variations, arrhythmia, and congestive heart failure also gravitate toward it.

• Gallbladder Issues: Octreotide acetate could downturn the gallbladder's contractility attributes. Furthermore, the release of bile acid also slows down. All these heighten the propensity for gallbladder issues like cholelithiasis, cholestatic hepatitis, biliary obstruction, and ascending cholangitis. Octreotide acetate injection therapy for one year or more could increase the propensity for gallstones by 52 percent.

• Thyroid Dysfunctions: Octreotide acetate injection therapy, in the long run, could bring out hypothyroidism by depleting thyroid-stimulating hormone release. Therefore, the functional attributes of the thyroid need to be weighed periodically.

• Deranged Blood Sugar Levels: Octreotide acetate injection therapy could instigate derangements in blood sugar proportions. These could either be hypoglycemia or hyperglycemia, owing to derangements in the glucagon and insulin hormones that modulate and tune the blood sugar level. Blood sugar level monitoring is, therefore, imperative during the Octreotide acetate injection therapy.

• Altered Dietary Absorption: Octreotide acetate injection therapy critically downturns intestinal uptake of dietary fat. Similarly, vitamin B12 proportions also downscale while on Octreotide acetate therapy.

Drug Interactions of Octreotide Acetate Injection

Octreotide’s interactions with other medicines include:

• Bromocriptine: Bromocriptine, when administered alongside Octreotide acetate, could bring out an upturn in the bioavailability of Bromocriptine, which increases the scope for Bromocriptine overdosing.

• Cyclosporin: Oral cyclosporin, when concomitantly introduced with Octreotide acetate, could downturn the uptake of oral cyclosporin. Thus, the expected effectiveness of Cyclosporin cannot be attained even with the preferred dose.

• Oral Hypoglycemic Drugs and Insulin: Octreotide acetate therapy could derange the release of glucagon and insulin. Therefore, while advocating Octreotide acetate alongside antidiabetic medicines, appropriate adjustments must be instituted in the dosage of antidiabetic drugs.

• Bradycardia-Inducing Drugs: Heightened heart rate depletion is demonstrated with the concomitant employment of Octreotide acetate and bradycardia-inducing drugs.

• Lutetium Lu 177 Dotatate Injection: Octreotide acetate injection, when concurrently delivered with Lutetium Lu 177 dotatate injection, palliates the therapeutic attributes of Lutetium.

• Drugs Metabolized by Cytochrome P3A4: Octreotide acetate, alongside other medicaments that are cytochrome P3A4 substrates, depletes and downturns their metabolic clearance. This is more relevant with drugs of low therapeutic index, as it enhances their scope for toxicity.

Specific Considerations:

• Octreotide Acetate Injection During Pregnancy: There is insufficient data on Octreotide Acetate injection in expectant women, making it challenging to conclude its safety and efficacy. Therefore, Octreotide Acetate ought to be advocated, taking into account the propensity for fetal harm and material health crises.

• Octreotide Acetate Injection During Lactation: Animal studies demonstrated that Octreotide Acetate could be expressed through maternal breast milk following subcutaneous delivery. However, more clarity is needed concerning the same in humans. Therefore, caution must be employed while advocating Octreotide Acetate to a nursing woman.

• Octreotide Acetate Injection for the Pediatric Population: Octreotide acetate injections are not routinely advisable for the pediatric population as their therapeutic attributes in that particular age group have not been demonstrated.

• Octreotide Acetate Injection for the Geriatric Population: The studies that evaluated and scrutinized the therapeutic attributes of Octreotide injections have yet to have an appreciable number of geriatric patients.